Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Acorda Buys Its Way Into A Parkinson's Franchise

This article was originally published in The Pink Sheet Daily

Executive Summary

Having acquired Parkinson's candidate CVT-301 in the 2014 purchase of Civitas, Acorda sees Biotie's Phase III tozadenant as an ideal candidate to create a complementary Parkinson's disease franchise.


Related Content

Sunovion Adds Parkinson's To CNS Franchise With Cynapsus Buyout
Merck Halts Preladenant Development In Parkinson’s Following Phase III Failures


Related Companies

Related Deals